Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M pro /3CL pro in Living Cells

著者: Seyed Arad Moghadasi, Morgan A. Esler, Yuka Otsuka, Jordan T. Becker, Sofia N. Moraes, Constance B. Anderson, Srinivas Chamakuri, Christopher Belica, Chloe Wick, Daniel A. Harki, Damian W. Young, Louis Scampavia, Timothy Spicer, Ke Shi, Hideki Aihara, William L. Brown, Reuben S. Harris - mBio 2022 被引用: 39

variants with altered susceptibilities to inhibition, triage-nonspecific, or off-target molecules and validate bona fide inhibitors, with the most potent thus far being the first-in-class drug nirmatrelvir.